1. Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity
- Author
-
Gao Bei, Tong Yang, Yanjun Liu, Teng Zhao, Hua Li, Yong Su, Zhang Yifan, Wu Guanghao, Lingyu Guan, Cai Junli, Ruiwen Song, Wu Jingsong, Sicheng Yin, Li Zhao, Li Jin, Helin Yu, Hengbin Zhang, Guo Qingsong, Xu Jun, Yijun Shen, and Cao Xuemei
- Subjects
musculoskeletal diseases ,congenital, hereditary, and neonatal diseases and abnormalities ,Immunoconjugates ,CD30 ,Immunology ,Drug Evaluation, Preclinical ,Ki-1 Antigen ,Antineoplastic Agents ,Mice, SCID ,Hodgkin’s disease ,03 medical and health sciences ,Mice ,0302 clinical medicine ,immune system diseases ,hemic and lymphatic diseases ,Report ,medicine ,Bystander effect ,Immunology and Allergy ,Animals ,Humans ,hematological malignancies ,cutaneous T-cell lymphoma ,Anaplastic large-cell lymphoma ,030304 developmental biology ,Brentuximab Vedotin ,0303 health sciences ,Antibody drug conjugate (ADC) ,biology ,integumentary system ,Chemistry ,Cutaneous T-cell lymphoma ,food and beverages ,medicine.disease ,Macaca fascicularis ,anaplastic large cell lymphoma ,030220 oncology & carcinogenesis ,Hematologic Neoplasms ,bystander effect ,biology.protein ,Cancer research ,Lymphoma, Large-Cell, Anaplastic ,Antimitotic Agent ,Antibody ,DM1 ,Linker ,Conjugate - Abstract
An anti-CD30 antibody-drug conjugate incorporating the antimitotic agent DM1 and a stable SMCC linker, anti-CD30-MCC-DM1, was generated as a new antitumor drug candidate for CD30-positive hematological malignancies. Here, the in vitro and in vivo pharmacologic activities of anti-CD30-MCC-DM1 (also known as F0002-ADC) were evaluated and compared with ADCETRIS (brentuximab vedotin). Pharmacokinetics (PK) and the safety profiles in cynomolgus monkeys were assessed. Anti-CD30-MCC-DM1 was effective in in vitro cell death assays using CD30-positive lymphoma cell lines. We studied the properties of anti-CD30-MCC-DM1, including binding, internalization, drug release and actions. Unlike ADCETRIS, anti-CD30-MCC-DM1 did not cause a bystander effect in this study. In vivo, anti-CD30-MCC-DM1 was found to be capable of inducing tumor regression in subcutaneous inoculation of Karpas 299 (anaplastic large cell lymphoma), HH (cutaneous T-cell lymphoma) and L428 (Hodgkin’s disease) cell models. The half-lives of 4 mg/kg and 12 mg/kg anti-CD30-MCC-DM1 were about 5 days in cynomolgus monkeys, and the tolerated dose was 30 mg/kg in non-human primates, supporting the tolerance of anti-CD30-MCC-DM1 in humans. These results suggest that anti-CD30-MCC-DM1 presents efficacy, safety and PK profiles that support its use as a valuable treatment for CD30-positive hematological malignancies.
- Published
- 2019